Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are:
- To confirm the safety and tolerability of magrolimab monotherapy in a
relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome
(MDS) population, and of magrolimab in combination with azacitidine in previously
untreated participants with AML or MDS and participants with R/R AML and MDS
- To evaluate the efficacy of magrolimab monotherapy in R/R AML/MDS, and of magrolimab in
combination with azacitidine in previously untreated participants with AML/MDS, or R/R
AML/MDS as measured by complete remission (CR) rate for participants with AML and
higher-risk MDS, and duration of complete response for participants with AML and
higher-risk MDS, and duration of CR for participants with AML and higher-risk MDS
- To evaluate the safety, tolerability, and efficacy of magrolimab monotherapy or
combination with azacitidine in low-risk MDS participants as measured by red blood cell
(RBC) transfusion independence rate